Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)-Reference-Cited by-同舟云学术

Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)

Published:2013-12-19 Issue:1 Volume:29 Page:260-267
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Díez-Pérez Adolfo¹²,Adachi Jonathan D³,Adami Silvano⁴,Anderson Frederick A⁵,Boonen Steven⁶,Chapurlat Roland⁷,Compston Juliet E⁸,Cooper Cyrus⁹,Gehlbach Stephen H⁵,Greenspan Susan L¹⁰,Hooven Frederick H⁵,LaCroix Andrea Z¹¹,Nieves Jeri W¹²,Netelenbos J Coen¹³,Pfeilschifter Johannes¹⁴,Rossini Maurizio¹⁵,Roux Christian¹⁶,Saag Kenneth G¹⁷,Silverman Stuart¹⁸,Siris Ethel S¹⁹,Wyman Allison⁵,Rushton-Smith Sophie K⁵,Watts Nelson B²⁰,

Affiliation:

1. Hospital del Mar-IMIM-Autonomous University of Barcelona; Barcelona Spain

2. Red Tematica Investigacion en Envejecimiento y Fragilidad (RETICEF); Instituto Carlos III; Barcelona Spain

3. St. Joseph's Hospital; McMaster University; Hamilton Ontario Canada

4. Department of Rheumatology; University of Verona; Ospedale Verona, Valeggio Italy

5. Center for Outcomes Research; University of Massachusetts Medical School; Worcester MA USA

6. Leuven University Center for Metabolic Bone Diseases; Division of Geriatric Medicine; Katholieke Universiteit Leuven; Leuven Belgium

7. Institut National de la Santé et de la Recherche Médicale (INSERM; National Institute of Health and Medical Research) U831; Université de Lyon, Division of Rheumatology, Hôpital E. Herriot; Lyon France

8. School of Clinical Medicine; Addenbrooke's Hospital; University of Cambridge; Cambridge UK

9. Medical Research Council (MRC) Lifecourse Epidemiology Unit; University of Southampton, Southampton General Hospital; Southampton UK

10. University of Pittsburgh; Pittsburgh; Pennsylvania USA

11. Fred Hutchinson Cancer Research Center; Seattle WA USA

12. Helen Hayes Hospital and Columbia University; West Haverstraw; New York USA

13. Department of Endocrinology; Vrije Universiteit (VU) University Medical Center; Amsterdam The Netherlands

14. Alfried Krupp Krankenhaus; Department of Internal Medicine III; Essen Germany

15. Department of Rheumatology; University of Verona; Verona Italy

16. Paris Descartes University; Cochin Hospital; Paris France

17. University of Alabama-Birmingham; Birmingham AL USA

18. Department of Rheumatology; Cedars-Sinai/University of California; Los Angeles (UCLA) Los Angeles, CA USA

19. Department of Medicine; Columbia University Medical Center; New York NY USA

20. Bone Health and Osteoporosis Center; University of Cincinnati; Cincinnati OH USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.2023/fullpdf

Reference21 articles.

1. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis;MacLean;Ann Intern Med.,2008

2. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial;Ettinger;JAMA.,1999

3. FIT Research Group. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial;Levis;J Am Geriatr Soc.,2002

4. Risedronate prevents new vertebral fractures in postmenopausal women at high risk;Watts;J Clin Endocrinol Metab.,2003

5. Effects of antiresorptive treatment on nonvertebral fracture outcomes;Mackey;J Bone Miner Res.,2011

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Osteoporosis and the Use of Digital Health Intervention;Artificial Intelligence for Bone Disorder;2024-01-26

2. Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature;Expert Opinion on Pharmacotherapy;2023-12-12

3. What are patients’ experiences of discontinuing clozapine and how does this impact their views on subsequent treatment?;BMC Psychiatry;2023-05-22

4. New Horizons: Artificial Intelligence Tools for Managing Osteoporosis;The Journal of Clinical Endocrinology & Metabolism;2022-12-08

5. Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry;Aging Clinical and Experimental Research;2022-04-18